Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression

[1]  R. L. Hollis,et al.  Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification , 2021, npj Precision Oncology.

[2]  J. Copland,et al.  Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers , 2020, ESMO Open.

[3]  Kylie L. Gorringe,et al.  Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities , 2020, The Journal of pathology.

[4]  V. Kristensen,et al.  Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer , 2020, Breast Cancer Research and Treatment.

[5]  D. Huntsman,et al.  Low-grade serous ovarian cancer: State of the science. , 2020, Gynecologic oncology.

[6]  A. Talhouk,et al.  Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. , 2020, Gynecologic oncology.

[7]  A. Sood,et al.  The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. , 2019, Gynecologic oncology.

[8]  Olga Tanaseichuk,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[9]  C. Denkert,et al.  Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. , 2019, Human pathology.

[10]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[11]  C. Cole,et al.  The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers , 2018, Nature Reviews Cancer.

[12]  Sebastian M. Armasu,et al.  Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study , 2018, The journal of pathology. Clinical research.

[13]  C. Le Page,et al.  Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers , 2018, BMC Cancer.

[14]  Dale W. Garsed,et al.  EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. , 2017, Cancer research.

[15]  E. Martinelli,et al.  Hormone receptor expression profile of low-grade serous ovarian cancers. , 2017, Gynecologic oncology.

[16]  N. Ahmed,et al.  Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling , 2017, Scientific Reports.

[17]  M. Köbel,et al.  Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications , 2017, International journal of molecular sciences.

[18]  D. Bodurka,et al.  Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Kun Yu,et al.  PureCN: copy number calling and SNV classification using targeted short read sequencing , 2016, Source Code for Biology and Medicine.

[20]  S. Leung,et al.  An Immunohistochemical Algorithm for Ovarian Carcinoma Typing , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[21]  A. Reuss,et al.  Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. , 2016, Gynecologic oncology.

[22]  P. Tauchi-Nishi,et al.  The LAST guidelines in clinical practice: implementing recommendations for p16 use. , 2015, American journal of clinical pathology.

[23]  Kylie L. Gorringe,et al.  Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes , 2015, Oncotarget.

[24]  D. Bodurka,et al.  Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Caroline H. Diep,et al.  Progesterone action in breast, uterine, and ovarian cancers. , 2015, Journal of molecular endocrinology.

[26]  Jos Jonkers,et al.  CopywriteR: DNA copy number detection from off-target sequence data , 2015, Genome Biology.

[27]  A. Whittemore,et al.  Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. , 2013, The Lancet. Oncology.

[28]  Caroline H. Diep,et al.  Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells , 2013, Cell cycle.

[29]  C. Le Page,et al.  Specimen quality evaluation in Canadian biobanks participating in the COEUR repository. , 2013, Biopreservation and biobanking.

[30]  G. Mills,et al.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.

[31]  G. Castellano,et al.  CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells. , 2012, Genes & development.

[32]  D. Bodurka,et al.  Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. , 2012, Gynecologic oncology.

[33]  K. Kinzler,et al.  Low‐grade serous carcinomas of the ovary contain very few point mutations , 2012, The Journal of pathology.

[34]  D. Bodurka,et al.  Clinicodemographic factors influencing outcomes in patients with low‐grade serous ovarian carcinoma , 2011, Cancer.

[35]  K. Darvishi.  Application of Nexus Copy Number Software for CNV Detection and Analysis , 2010, Current protocols in human genetics.

[36]  Shan Wang-Gohrke,et al.  ESR1/SYNE1 Polymorphism and Invasive Epithelial Ovarian Cancer Risk: An Ovarian Cancer Association Consortium Study , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[37]  A. Sood,et al.  Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. , 2009, Gynecologic oncology.

[38]  Mike Tyers,et al.  BioGRID: a general repository for interaction datasets , 2005, Nucleic Acids Res..

[39]  M. Y. Kim,et al.  NAD+-Dependent Modulation of Chromatin Structure and Transcription by Nucleosome Binding Properties of PARP-1 , 2004, Cell.

[40]  Robert W. Rudd,et al.  OF THE STATE OF THE SCIENCE * , 2002 .

[41]  John Van Hoewyk,et al.  A multivariate technique for multiply imputing missing values using a sequence of regression models , 2001 .

[42]  K. Horwitz,et al.  Association of the Ku autoantigen/DNA-dependent protein kinase holoenzyme and poly(ADP-ribose) polymerase with the DNA binding domain of progesterone receptors. , 2000, Journal of molecular endocrinology.

[43]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .